| pubmed-article:8435663 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0376152 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C1548399 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:8435663 | lifeskim:mentions | umls-concept:C0163054 | lld:lifeskim |
| pubmed-article:8435663 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8435663 | pubmed:dateCreated | 1993-3-25 | lld:pubmed |
| pubmed-article:8435663 | pubmed:abstractText | In August 1988 we began a program in which multiple myeloma patients achieving < or = 10% marrow plasma cells and > or = 50% reduction in paraprotein levels after the VAD (vincristine, doxorubicin, dexamethasone) regimen underwent bone marrow harvest, ex vivo marrow purging with 4-hydroperoxycyclophosphamide (4-HC) and marrow cryopreservation. Conditioning with a regimen of high-dose busulfan (total dose 16 mg/kg), cyclophosphamide (120 mg/kg) and melphalan (90 mg/m2) (BU + CY + MEL) followed by autologous BMT was then carried out. Seventeen of the 24 patients who received VAD (71%, 95% confidence interval [CI] 49 to 87%) were eligible for bone marrow harvest. One patient was not harvested because of non-medical reasons; two patients who underwent marrow harvest had gross plasmacytosis present in biopsies performed intraoperatively and did not undergo BMT. Fourteen patients (58%, 95% CI 37 to 78%) received BU + CY + MEL and 4-HC-purged autologous BMT. The median time to recovery of 0.5 x 10(9)/l neutrophils was 19 days (range 14 to 26) while the last platelet transfusion was given on a median of day 32 (range 10 to 46) post-BMT in the evaluable patients. The major non-hematologic toxicity was hepatic; two patients in complete remission died of hepatic veno-occlusive disease. Another patient succumbed to fungal infection despite neutrophil recovery. The remaining 11 patients achieved responses (complete in six and partial in five) associated with a normal performance status.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:8435663 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8435663 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8435663 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8435663 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8435663 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8435663 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:ShepherdJ DJD | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:PhillipsG LGL | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:ConnorsJ MJM | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:KlingemannH... | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:SutherlandH... | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:BarnettM JMJ | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:O'ReillyS ESE | lld:pubmed |
| pubmed-article:8435663 | pubmed:author | pubmed-author:ReeceD EDE | lld:pubmed |
| pubmed-article:8435663 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8435663 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:8435663 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8435663 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8435663 | pubmed:pagination | 139-46 | lld:pubmed |
| pubmed-article:8435663 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:meshHeading | pubmed-meshheading:8435663-... | lld:pubmed |
| pubmed-article:8435663 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8435663 | pubmed:articleTitle | Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. | lld:pubmed |
| pubmed-article:8435663 | pubmed:affiliation | Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Canada. | lld:pubmed |
| pubmed-article:8435663 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8435663 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8435663 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8435663 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8435663 | lld:pubmed |
